Pfizer Inc and BioNTech SE announced today that they have initiated mid-level trials of a modified Covid-19 vaccine that targets both the original variants and the BA.2 Omicron sub-variant.
The vaccine is in an initial proof-of-concept study to gather more data (https://bit.ly/3veWPKn).
The BA.4 and BA.5 subvariants combined are estimated to account for nearly 95% of the subvariants in circulation in the United States in the week ending July 23.
The US Food and Drug Administration last month asked companies to make vaccines that target the BA.4 and BA.5 subvariants, which are currently the dominant ones, for a possible booster in the fall.
I am Derek Black, an author of World Stock Market. I have a degree in creative writing and journalism from the University of Central Florida. I have a passion for writing and informing the public. I strive to be accurate and fair in my reporting, and to provide a voice for those who may not otherwise be heard.